Qun Cheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Qun Cheng has a total of 145 co-authors. Here are the top co-authors by number of shared publications:
Wenjing Tang
Research Section of Geriatric Metabolic Bone Disease, Shanghai Geriatric Institute, Department of Osteoporosis and Bone Disease Huadong Hospital, Fudan University Shanghai China
9 shared publicationsMinmin Chen
Research Section of Geriatric Metabolic Bone Disease, Shanghai Geriatric Institute, Department of Osteoporosis and Bone Disease Huadong Hospital, Fudan University Shanghai China
8 shared publicationsHuilin Li
Research Section of Geriatric Metabolic Bone Disease, Shanghai Geriatric Institute, Department of Osteoporosis and Bone Disease Huadong Hospital, Fudan University Shanghai China
7 shared publicationsYanping Du
Department of Osteoporosis and Bone Disease, Research Section of Geriatric Metabolic Bone Disease, Huadong Hospital Affiliated to Fudan University, Shanghai Geriatric Institute, Shanghai, China
7 shared publicationsWeijia Yu
Research Section of Geriatric Metabolic Bone Disease, Shanghai Geriatric Institute, Department of Osteoporosis and Bone Disease Huadong Hospital, Fudan University Shanghai China
6 shared publicationsHongli Shi
Department of Osteoporosis and Bone Disease, Huadong Hospital Affiliated to Fudan University, Research Section of Geriatric Metabolic Bone Disease, Shanghai Geriatric Institute, Shanghai, China
5 shared publications
Latest Publications
- Open Access
- 3 June 2026
- Published by Elsevier in Journal of Orthopaedic Translation
- Vol. 59, 101135
Romosozumab increases bone mineral density in postmenopausal Chinese women with osteoporosis: A randomised phase three study
- 3 June 2026
- Published by Elsevier in Journal of Orthopaedic Translation
- Vol. 59, 101135
Open AccessRomosozumab increases bone mineral density in postmenopausal Chinese women with osteoporosis: A randomised phase three study
- Open Access
- 23 April 2026
- Published by Wiley in Aging Medicine
- Vol. 9 (2) , 129-136
Predictive Model Development and Validation for Low Appendicular Skeletal Muscle Mass in Chinese Older Adults
Objectives: Low skeletal muscle mass is associated with adverse clinical outcomes. Due to constraints related to cost and equipment availability, direct measurement of skeletal muscle mass is often not feasible in routine practice. This study aimed to develop and validate a practical predictive model for identifying low appendicular skeletal muscle mass (ASMM) in older adults. Methods: Body composition was assessed using DXA in the development group and BIA in the validation group. Standard questionnaires and anthropometric measurements were completed by trained testers. A predictive model was developed through multivariable binary logistic regression analysis and subsequently underwent external validation using an independent cohort to evaluate its generalizability. Results: A total of 393 elderly adults, aged 60–86 years (204 males, 189 females) participated in the study. The prevalence of Low ASMI was 74.0% in males and 58.2% in females. A predictive model for low ASMI was developed as Y = 75‐BMI‐CC (+10 if male). ROC analysis showed an AUC of 0.808 in the model development group, with sensitivity and specificity of 88.7% and 43.4% in males, and 83.6% and 44.3% in females, respectively. The model also demonstrated high accuracy in predicting low ASMI in the validation group. Using the prediction model, participants were categorized into three risk groups: high risk, low risk, and intermediate risk. The low‐risk category, for whom skeletal muscle mass measurement is probably unnecessary, represented 28.9% of males and 9.2% of females. Conclusions: This simple predictive model provides an easily calculable tool for estimating low ASMM in daily clinical practice and can facilitate the screening for reduced skeletal muscle mass in older adults.
- 23 April 2026
- Published by Wiley in Aging Medicine
- Vol. 9 (2) , 129-136
Open AccessPredictive Model Development and Validation for Low Appendicular Skeletal Muscle Mass in Chinese Older Adults
Objectives: Low skeletal muscle mass is associated with adverse clinical outcomes. Due to constraints related to cost and equipment availability, direct measurement of skeletal muscle mass is often not feasible in routine practice. This study aimed to develop and validate a practical predictive model for identifying low appendicular skeletal muscle mass (ASMM) in older adults. Methods: Body composition was assessed using DXA in the development group and BIA in the validation group. Standard questionnaires and anthropometric measurements were completed by trained testers. A predictive model was developed through multivariable binary logistic regression analysis and subsequently underwent external validation using an independent cohort to evaluate its generalizability. Results: A total of 393 elderly adults, aged 60–86 years (204 males, 189 females) participated in the study. The prevalence of Low ASMI was 74.0% in males and 58.2% in females. A predictive model for low ASMI was developed as Y = 75‐BMI‐CC (+10 if male). ROC analysis showed an AUC of 0.808 in the model development group, with sensitivity and specificity of 88.7% and 43.4% in males, and 83.6% and 44.3% in females, respectively. The model also demonstrated high accuracy in predicting low ASMI in the validation group. Using the prediction model, participants were categorized into three risk groups: high risk, low risk, and intermediate risk. The low‐risk category, for whom skeletal muscle mass measurement is probably unnecessary, represented 28.9% of males and 9.2% of females. Conclusions: This simple predictive model provides an easily calculable tool for estimating low ASMM in daily clinical practice and can facilitate the screening for reduced skeletal muscle mass in older adults.
- Open Access
- 18 August 2025
- Published by Oxford University Press (OUP) in JBMR Plus
- Vol. 9 (10) , ziaf135
A novel dominant negative variant of ALPL induces hypophosphatasia
Hypophosphatemia (HPP) is an inherited metabolic disorder characterized by defective bone and tooth mineralization, resulting from mutations in the gene encoding tissue-nonspecific alkaline phosphatase (ALPL). Despite the wide spectrum of clinical manifestations associated with ALPL mutations, the genotype–phenotype relationship remains poorly understood. In this work, we discovered a novel combination of missense mutations, p.G129E and p.Y263H. The patient with the mutations suffered from chronic musculoskeletal pain, arthralgia, and permanent dentition. Biochemical assays revealed that the Y263H mutation did not impair enzymatic function, but the G129E mutation significantly disrupted catalytic activity. Furthermore, G129E exhibited a dominant-negative effect by suppressing the function of the WT ALPL protein. Molecular dynamics simulations indicated that E129 formed novel salt bridges with R152, altering correlated motions and conformational dynamics of ALPL. These changes likely impair the formation of ALPL octamers, leading to loss of enzymatic activity. These findings establish a novel genotype–phenotype association in HPP and highlight the importance of accurate diagnosis to prevent the inappropriate use of bone resorption inhibitors in misdiagnosed patients.
- 18 August 2025
- Published by Oxford University Press (OUP) in JBMR Plus
- Vol. 9 (10) , ziaf135
Open AccessA novel dominant negative variant of ALPL induces hypophosphatasia
Hypophosphatemia (HPP) is an inherited metabolic disorder characterized by defective bone and tooth mineralization, resulting from mutations in the gene encoding tissue-nonspecific alkaline phosphatase (ALPL). Despite the wide spectrum of clinical manifestations associated with ALPL mutations, the genotype–phenotype relationship remains poorly understood. In this work, we discovered a novel combination of missense mutations, p.G129E and p.Y263H. The patient with the mutations suffered from chronic musculoskeletal pain, arthralgia, and permanent dentition. Biochemical assays revealed that the Y263H mutation did not impair enzymatic function, but the G129E mutation significantly disrupted catalytic activity. Furthermore, G129E exhibited a dominant-negative effect by suppressing the function of the WT ALPL protein. Molecular dynamics simulations indicated that E129 formed novel salt bridges with R152, altering correlated motions and conformational dynamics of ALPL. These changes likely impair the formation of ALPL octamers, leading to loss of enzymatic activity. These findings establish a novel genotype–phenotype association in HPP and highlight the importance of accurate diagnosis to prevent the inappropriate use of bone resorption inhibitors in misdiagnosed patients.
- Open Access
- 1 May 2025
- Published by Taylor & Francis in Clinical Interventions in Aging
- Vol. ume 20, 573-586
Impacts of Prior Anti-Osteoporosis Treatments on Sequential Denosumab Responses in BMD Changes Among Postmenopausal Osteoporosis Women in East China: Real-World Data Analysis
Purpose: This study aimed to investigate the impacts of prior anti-osteoporosis treatments on bone mineral density (BMD) changes in Chinese postmenopausal women with osteoporosis following 1-year Denosumab (Dmab) therapy. Patients and Methods: This retrospective cohort study enrolled 381 postmenopausal women, all receiving a 1-year Dmab treatment. Participants were stratified into five groups based on prior anti-osteoporosis treatments: no treatment (NT), alendronate (ALN), zoledronic acid (ZOL), teriparatide (TPT), and raloxifene (RAL). Potential factors influencing BMD changes were screened using least absolute shrinkage and selection operator (LASSO). The selected variables were then incorporated into a multivariate regression model to identify independent risk factors. Finally, after adjusting for confounders, the impacts of prior anti-osteoporosis treatment on sequential Dmab responses were evaluated. Results: 1) Further BMD increases were observed after sequential 1-year Dmab with prior use of other anti-osteoporosis drugs; 2) Compared to the NT group, ZOL significantly reduced BMD changes at the lumbar spine (LS), femoral neck (FN), and total hip (TH) (LS: β = − 0.01, P = 0.016; FN: β = − 0.01, P = 0.010; TH: β = − 0.01, P = 0.011); Significant negative associations with FN BMD changes were observed for the ALN group (β = − 0.01, P< 0.001), and the RAL group (β = − 0.01, P = 0.010) compared to the NT group; TPT showed no significant differences with the NT group at all sites; 3) Multiple analysis revealed baseline BMD were independently associated with changes in BMD (LS: β = − 0.04, P = 0.009; FN: β = − 0.19, P < 0.001; TH: β = − 0.14, P < 0.001). Conclusion: These findings indicated that prior anti-osteoporosis treatments differentially influenced BMD responses to 1-year Dmab therapy. While patients who had previously been treated with ZOL had limited subsequent BMD improvement, patients who had previously used TPT and had lower baseline BMD benefited more.
- 1 May 2025
- Published by Taylor & Francis in Clinical Interventions in Aging
- Vol. ume 20, 573-586
Open AccessImpacts of Prior Anti-Osteoporosis Treatments on Sequential Denosumab Responses in BMD Changes Among Postmenopausal Osteoporosis Women in East China: Real-World Data Analysis
Purpose: This study aimed to investigate the impacts of prior anti-osteoporosis treatments on bone mineral density (BMD) changes in Chinese postmenopausal women with osteoporosis following 1-year Denosumab (Dmab) therapy. Patients and Methods: This retrospective cohort study enrolled 381 postmenopausal women, all receiving a 1-year Dmab treatment. Participants were stratified into five groups based on prior anti-osteoporosis treatments: no treatment (NT), alendronate (ALN), zoledronic acid (ZOL), teriparatide (TPT), and raloxifene (RAL). Potential factors influencing BMD changes were screened using least absolute shrinkage and selection operator (LASSO). The selected variables were then incorporated into a multivariate regression model to identify independent risk factors. Finally, after adjusting for confounders, the impacts of prior anti-osteoporosis treatment on sequential Dmab responses were evaluated. Results: 1) Further BMD increases were observed after sequential 1-year Dmab with prior use of other anti-osteoporosis drugs; 2) Compared to the NT group, ZOL significantly reduced BMD changes at the lumbar spine (LS), femoral neck (FN), and total hip (TH) (LS: β = − 0.01, P = 0.016; FN: β = − 0.01, P = 0.010; TH: β = − 0.01, P = 0.011); Significant negative associations with FN BMD changes were observed for the ALN group (β = − 0.01, P< 0.001), and the RAL group (β = − 0.01, P = 0.010) compared to the NT group; TPT showed no significant differences with the NT group at all sites; 3) Multiple analysis revealed baseline BMD were independently associated with changes in BMD (LS: β = − 0.04, P = 0.009; FN: β = − 0.19, P < 0.001; TH: β = − 0.14, P < 0.001). Conclusion: These findings indicated that prior anti-osteoporosis treatments differentially influenced BMD responses to 1-year Dmab therapy. While patients who had previously been treated with ZOL had limited subsequent BMD improvement, patients who had previously used TPT and had lower baseline BMD benefited more.
- Open Access
- 2 September 2024
- Published by Springer Nature in BMC Musculoskeletal Disorders
- Vol. 25 (1) , 1-12
Change in body temperature, not acute-phase reaction, predict anti-Osteoporosis efficacy after the first administration of Zoledronic acid: a prospective observational cohort study
Acute-phase reactions (APRs) are common among people treated for the first time with zoledronate (ZOL). The current view is that both the APRs caused by ZOL and its efficacy are related to the mevalonic acid pathway. However, the relationship between APRs and ZOL efficacy remains unclear. This was a prospective observational cohort study involving postmenopausal women with osteoporosis in Shanghai, China, for 1 year. A total of 108 patients with an average age of 67.4 ± 5.8 years were treated with 5 mg intravenous ZOL for the first time. Data on demographic characteristics, APRs, blood counts, bone turnover markers, including C-telopeptide collagen crosslinks (CTX) and N-terminal propeptide of type 1 collagen (PINP), and bone mineral density (BMD) were collected. (1) The results did not reveal a relationship between APRs and changes in bone turnover markers and BMD but showed that changes in body temperature (T) within 3 days after administration were positively correlated with changes in the BMD of the LS at Month 12 (β = 0.279 P = 0.034). (2) This effect was mediated mainly by changes in serum CTX (b = 0.046, 95% CI [0.0010–0.0091]). (3) The ROC curve revealed that when T increased by 1.95 °C, the sensitivity and specificity of identifying clinically important changes in LS BMD after 1 year were optimized. In this study, we tested the hypothesis that people with elevated body T after initial ZOL treatment had greater improvements in BMD and better outcomes. NCT, NCT03158246. Registered 18/05/2017.
- 2 September 2024
- Published by Springer Nature in BMC Musculoskeletal Disorders
- Vol. 25 (1) , 1-12
Open AccessChange in body temperature, not acute-phase reaction, predict anti-Osteoporosis efficacy after the first administration of Zoledronic acid: a prospective observational cohort study
Acute-phase reactions (APRs) are common among people treated for the first time with zoledronate (ZOL). The current view is that both the APRs caused by ZOL and its efficacy are related to the mevalonic acid pathway. However, the relationship between APRs and ZOL efficacy remains unclear. This was a prospective observational cohort study involving postmenopausal women with osteoporosis in Shanghai, China, for 1 year. A total of 108 patients with an average age of 67.4 ± 5.8 years were treated with 5 mg intravenous ZOL for the first time. Data on demographic characteristics, APRs, blood counts, bone turnover markers, including C-telopeptide collagen crosslinks (CTX) and N-terminal propeptide of type 1 collagen (PINP), and bone mineral density (BMD) were collected. (1) The results did not reveal a relationship between APRs and changes in bone turnover markers and BMD but showed that changes in body temperature (T) within 3 days after administration were positively correlated with changes in the BMD of the LS at Month 12 (β = 0.279 P = 0.034). (2) This effect was mediated mainly by changes in serum CTX (b = 0.046, 95% CI [0.0010–0.0091]). (3) The ROC curve revealed that when T increased by 1.95 °C, the sensitivity and specificity of identifying clinically important changes in LS BMD after 1 year were optimized. In this study, we tested the hypothesis that people with elevated body T after initial ZOL treatment had greater improvements in BMD and better outcomes. NCT, NCT03158246. Registered 18/05/2017.
- Open Access
- 19 December 2023
- Published by Springer Nature in Skeletal Muscle
- Vol. 13 (1) , 1-13
Eldecalcitol prevents muscle loss and osteoporosis in disuse muscle atrophy via NF-κB signaling in mice
We investigated the effect of eldecalcitol on disuse muscle atrophy. C57BL/6J male mice aged 6 weeks were randomly assigned to control, tail suspension (TS), and TS-eldecalcitol–treated groups and were injected intraperitoneally twice a week with either vehicle (control and TS) or eldecalcitol at 3.5 or 5 ng for 3 weeks. Grip strength and muscle weights of the gastrocnemius (GAS), tibialis anterior (TA), and soleus (SOL) were determined. Oxidative stress was evaluated by malondialdehyde, superoxide dismutase, glutathione peroxidase, and catalase. Bone microarchitecture was analyzed using microcomputed tomography. The effect of eldecalcitol on C2C12 myoblasts was analyzed by measuring myofibrillar protein MHC and the atrophy markers Atrogin-1 and MuRF-1 using immunofluorescence. The influence of eldecalcitol on NF-κB signaling pathway and vitamin D receptor (VDR) was assessed through immunofluorescence, (co)-immunoprecipitation, and VDR knockdown studies. Eldecalcitol increased grip strength (P < 0.01) and restored muscle loss in GAS, TA, and SOL (P < 0.05 to P < 0.001) induced by TS. An improvement was noted in bone mineral density and bone architecture in the eldecalcitol group. The impaired oxidative defense system was restored by eldecalcitol (P < 0.05 to P < 0.01 vs. TS). Eldecalcitol (10 nM) significantly inhibited the expression of MuRF-1 (P < 0.001) and Atrogin-1 (P < 0.01), increased the diameter of myotubes (P < 0.05), inhibited the expression of P65 and P52 components of NF-κB and P65 nuclear location, thereby inhibiting NF-κB signaling. Eldecalcitol promoted VDR binding to P65 and P52. VDR signaling is required for eldecalcitol-mediated anti-atrophy effects. In conclusion, eldecalcitol exerted its beneficial effects on disuse-induced muscle atrophy via NF-κB inhibition.
- 19 December 2023
- Published by Springer Nature in Skeletal Muscle
- Vol. 13 (1) , 1-13
Open AccessEldecalcitol prevents muscle loss and osteoporosis in disuse muscle atrophy via NF-κB signaling in mice
We investigated the effect of eldecalcitol on disuse muscle atrophy. C57BL/6J male mice aged 6 weeks were randomly assigned to control, tail suspension (TS), and TS-eldecalcitol–treated groups and were injected intraperitoneally twice a week with either vehicle (control and TS) or eldecalcitol at 3.5 or 5 ng for 3 weeks. Grip strength and muscle weights of the gastrocnemius (GAS), tibialis anterior (TA), and soleus (SOL) were determined. Oxidative stress was evaluated by malondialdehyde, superoxide dismutase, glutathione peroxidase, and catalase. Bone microarchitecture was analyzed using microcomputed tomography. The effect of eldecalcitol on C2C12 myoblasts was analyzed by measuring myofibrillar protein MHC and the atrophy markers Atrogin-1 and MuRF-1 using immunofluorescence. The influence of eldecalcitol on NF-κB signaling pathway and vitamin D receptor (VDR) was assessed through immunofluorescence, (co)-immunoprecipitation, and VDR knockdown studies. Eldecalcitol increased grip strength (P < 0.01) and restored muscle loss in GAS, TA, and SOL (P < 0.05 to P < 0.001) induced by TS. An improvement was noted in bone mineral density and bone architecture in the eldecalcitol group. The impaired oxidative defense system was restored by eldecalcitol (P < 0.05 to P < 0.01 vs. TS). Eldecalcitol (10 nM) significantly inhibited the expression of MuRF-1 (P < 0.001) and Atrogin-1 (P < 0.01), increased the diameter of myotubes (P < 0.05), inhibited the expression of P65 and P52 components of NF-κB and P65 nuclear location, thereby inhibiting NF-κB signaling. Eldecalcitol promoted VDR binding to P65 and P52. VDR signaling is required for eldecalcitol-mediated anti-atrophy effects. In conclusion, eldecalcitol exerted its beneficial effects on disuse-induced muscle atrophy via NF-κB inhibition.
- Open Access
Association between Serum Oxytocin, Bone Mineral Density and Body Composition in Chinese Adult Females
Background and Objectives: Oxytocin (OT) is a neuropeptide hormone which is known for its classical effects in pregnancy and lactation. Recently, growing evidence demonstrated a close relation between OT and bone. The present study aimed to explore the relationship between OT, bone and osteoporosis risk in Chinese adult females. Materials and Methods: in total, 149 adult females were enrolled. The serum OT levels were measured using ELISA kits. Bone mineral density (BMD) and body composition were measured by dual-energy X-ray absorptiometry (DXA). The study subjects were divided into two groups according to their menopause status and then divided into tertiles based on their serum OT level. Results: Serum OT, serum estradiol and BMD at three skeletal sites were significantly higher in the premenopausal group than in the postmenopausal group (p < 0.001, p = 0.008 and p < 0.001, respectively). In the tertile analysis, relative to tertile 1, significant associations were found for tertile 3 for OT levels and higher BMD in the femoral neck and total hip, in both pre- and postmenopausal groups. Using logistic regression analysis, tertile 3 appeared less likely to have low-BMD osteoporosis than tertile 1 (OR = 0.257, 95% CI = 0.073, 0.910). In multivariate stepwise regression analysis, OT and total lean mass were two positive determinants of BMD in the femoral neck and total hip in the premenopausal group (adjusted R2 for the model = 0.232 and 0.199, respectively; both p < 0.001). Conclusion: Our study demonstrated positive associations between serum OT levels and BMD in a Chinese (non-Caucasian) population. OT appeared to be more strongly associated with hip BMD in premenopausal females. These results may suggest a protective role and potential therapeutic use of OT in osteoporosis, especially for premenopausal women.
Open AccessAssociation between Serum Oxytocin, Bone Mineral Density and Body Composition in Chinese Adult Females
Background and Objectives: Oxytocin (OT) is a neuropeptide hormone which is known for its classical effects in pregnancy and lactation. Recently, growing evidence demonstrated a close relation between OT and bone. The present study aimed to explore the relationship between OT, bone and osteoporosis risk in Chinese adult females. Materials and Methods: in total, 149 adult females were enrolled. The serum OT levels were measured using ELISA kits. Bone mineral density (BMD) and body composition were measured by dual-energy X-ray absorptiometry (DXA). The study subjects were divided into two groups according to their menopause status and then divided into tertiles based on their serum OT level. Results: Serum OT, serum estradiol and BMD at three skeletal sites were significantly higher in the premenopausal group than in the postmenopausal group (p < 0.001, p = 0.008 and p < 0.001, respectively). In the tertile analysis, relative to tertile 1, significant associations were found for tertile 3 for OT levels and higher BMD in the femoral neck and total hip, in both pre- and postmenopausal groups. Using logistic regression analysis, tertile 3 appeared less likely to have low-BMD osteoporosis than tertile 1 (OR = 0.257, 95% CI = 0.073, 0.910). In multivariate stepwise regression analysis, OT and total lean mass were two positive determinants of BMD in the femoral neck and total hip in the premenopausal group (adjusted R2 for the model = 0.232 and 0.199, respectively; both p < 0.001). Conclusion: Our study demonstrated positive associations between serum OT levels and BMD in a Chinese (non-Caucasian) population. OT appeared to be more strongly associated with hip BMD in premenopausal females. These results may suggest a protective role and potential therapeutic use of OT in osteoporosis, especially for premenopausal women.
- Open Access
- 28 October 2022
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 1018480
Eldecalcitol prevents muscle loss by suppressing PI3K/AKT/FOXOs pathway in orchiectomized mice
Elderly male patients are susceptible to develop osteoporosis and sarcopenia, especially those with fragility fractures, hypogonadism, and prostate cancer with androgen deprivation therapy. However, at present, very few treatments are available for men with sarcopenia. Previous preclinical studies in ovariectomized rats have shown the promising effects of eldecalcitol in ameliorating the bone strength and muscle atrophy. We thus investigated the effects of eldecalcitol on androgen-deficient male mice. Six-week-old male mice underwent orchiectomy (ORX) or sham surgery. Mice were randomly divided into 4 groups (n = 12/per group), including 1) sham mice, 2) ORX group, 3) ORX eldecalcitol 30 ng/kg, and 4) ORX eldecalcitol 50 ng/kg. Eldecalcitol increased bone mass and strength of femur in ORX mice. Eldecalcitol 30 ng/kg dose completely rescued ORX-induced muscle weakness. The RT-qPCR showed that eldecalcitol enhanced the mRNA levels of type I and IIa fibers. The expression levels of MuRF1 and Atrogin-1 of gastrocnemius in the eldecalcitol groups were much lower than that of the ORX group. It is assumed that eldecalcitol potentially acts via PI3K/AKT/FOXOs signaling pathway. These findings provide evidence for evaluating eldecalcitol as an investigational treatment for male patients with sarcopenia and osteoporosis.
- 28 October 2022
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 1018480
Open AccessEldecalcitol prevents muscle loss by suppressing PI3K/AKT/FOXOs pathway in orchiectomized mice
Elderly male patients are susceptible to develop osteoporosis and sarcopenia, especially those with fragility fractures, hypogonadism, and prostate cancer with androgen deprivation therapy. However, at present, very few treatments are available for men with sarcopenia. Previous preclinical studies in ovariectomized rats have shown the promising effects of eldecalcitol in ameliorating the bone strength and muscle atrophy. We thus investigated the effects of eldecalcitol on androgen-deficient male mice. Six-week-old male mice underwent orchiectomy (ORX) or sham surgery. Mice were randomly divided into 4 groups (n = 12/per group), including 1) sham mice, 2) ORX group, 3) ORX eldecalcitol 30 ng/kg, and 4) ORX eldecalcitol 50 ng/kg. Eldecalcitol increased bone mass and strength of femur in ORX mice. Eldecalcitol 30 ng/kg dose completely rescued ORX-induced muscle weakness. The RT-qPCR showed that eldecalcitol enhanced the mRNA levels of type I and IIa fibers. The expression levels of MuRF1 and Atrogin-1 of gastrocnemius in the eldecalcitol groups were much lower than that of the ORX group. It is assumed that eldecalcitol potentially acts via PI3K/AKT/FOXOs signaling pathway. These findings provide evidence for evaluating eldecalcitol as an investigational treatment for male patients with sarcopenia and osteoporosis.
- Open Access
- 24 August 2022
- Published by Elsevier in Journal of Orthopaedic Translation
- Vol. 35, 53-61
Jintiange combined with alfacalcidol improves muscle strength and balance in primary osteoporosis: A randomized, double-blind, double-dummy, positive-controlled, multicenter clinical trial
- 24 August 2022
- Published by Elsevier in Journal of Orthopaedic Translation
- Vol. 35, 53-61
Open AccessJintiange combined with alfacalcidol improves muscle strength and balance in primary osteoporosis: A randomized, double-blind, double-dummy, positive-controlled, multicenter clinical trial